Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5 Lymphoid 3 Myeloid 2 Plasma cell 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 882 Bortezomib 481 Lenalidomide 467 Cyclophosphamide 367 Melphalan 276 Calcium Dobesilate 265 daratumumab 241 pomalidomide 216 carfilzomib 188 fludarabine phosphate 141 fludarabine 137 Thalidomide 125 Peripheral Blood Stem Cell Transplantation 120 Filgrastim 115 ixazomib 94 Mycophenolic Acid 91 Granulocyte Colony-Stimulating Factor 90 Busulfan 89 Whole-Body Irradiation 88 dexamethasone acetate 87 Tacrolimus 79 dexamethasone 21-phosphate 74 isatuximab 70 Cyclosporine 68 auricularum 67 Prednisone 67 elotuzumab 63 belantamab mafodotin 60 Antilymphocyte Serum 56 Etoposide 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

letermovir × Plasma cell × Clear all

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡